Here’s why Elon Musk lost his suit against OpenAI

On Monday, the jury in Musk v. Altman dealt Elon Musk a major blow—reaching a unanimous advisory verdict that he had sued OpenAI too late and, as a result, his claims are barred by the applicable statutes of limitations. US District Judge Yvonne Gonzalez Rogers immediately accepted it. 

Musk announced on X that he will be appealing the decision. “The judge & jury never actually ruled on the merits of the case, just on a calendar technicality,” he wrote.

OpenAI was cofounded by Musk and a group of researchers in 2015 as a nonprofit with a mission to develop AI for the benefit of humanity, unconstrained by a need to generate financial returns. Musk donated $38 million to the company during its early days, allegedly on the basis that OpenAI CEO Sam Altman and president Greg Brockman had promised to keep the company a nonprofit committed to the mission.   

Musk brought two claims against OpenAI. First, he argued that Altman and Brockman breached the charitable trust he created through his donations by breaking their promise to keep the company a nonprofit and creating a for-profit subsidiary that ballooned over the years. Second, he argued that Altman and Brockman unjustly enriched themselves at Musk’s expense. He sued OpenAI in 2024. 

Musk asked the court to unwind a 2025 restructuring that converted OpenAI’s for-profit subsidiary into a public benefit corporation and to remove Altman and Brockman from their roles.

OpenAI argued that the time for Musk to sue the company had run out before he brought the case. The statute of limitations on the breach of charitable trust claim is three years, while the statute of limitations on the unjust enrichment claim is two years. This means that Musk should have discovered, or had reason to discover, Altman and Brockman’s alleged breach of charitable trust no earlier than 2021 and their alleged unjust enrichment no earlier than 2022. 

While Musk argued he discovered that Altman and Brockman had broken their promise only in 2022, OpenAI claimed that Musk had reason to think this well before 2021. 

Musk told the jury that he has gone through “three phases” in his beliefs about OpenAI: In phase one, he was “enthusiastically supportive” of the company. In phase two, “I started to lose confidence that they were telling me the truth,” he said. In phase three, “I’m sure they’re looting the nonprofit.” 

Here’s a deeper dive into a timeline of the events as testified in the trial. You can read my dispatches from all three weeks of the trial here and here and here

2017: Musk proposes creating a for-profit subsidiary

In 2017, two years after OpenAI was founded, Musk and the other cofounders tried to create a for-profit subsidiary to raise enough capital to build artificial general intelligence—powerful AI that can compete with humans on most cognitive tasks. They fought a bitter power battle over who would get to control the entity. Musk also proposed merging OpenAI with his electric-car company, Tesla. 

During the trial, OpenAI’s lawyers pressed Musk on these discussions, suggesting that Musk knew in 2017 about Altman and Brockman’s plans to pivot the company—even participating in such plans—and had reason to sue then.

“I was not opposed to there being a small for-profit that provides funding to the nonprofit,” Musk told the jury, “as long as the tail didn’t wag the dog.” 

2019: OpenAI creates a for-profit subsidiary with capped profits

In 2019, OpenAI created a for-profit subsidiary, under which employees and investors would receive a capped return on their investment. At the same time, the company secured a $1 billion investment from Microsoft. OpenAI argued that Musk again had reason to sue the company then. 

But Musk testified that he didn’t think the move was violating the nonprofit’s mission. “If you’ve got a capped-profit situation, it hasn’t violated the nonprofit’s goal,” Musk told the jury earlier in the trial. “There was no basis for me to file a lawsuit at that time.”

2020: Microsoft snags an exclusive license 

In 2020, when Microsoft secured an exclusive license to OpenAI’s GPT-3 model, Musk posted on X: “This does seem like the opposite of open. OpenAI is essentially captured by Microsoft.” OpenAI once again argued that Musk had reason to sue then. 

But Musk testified that after reading the post, Altman reassured him that “OpenAI was staying on the mission as a nonprofit.” Musk said although he was skeptical, he still had no reason to sue the company at that point.

2022: Microsoft prepares to invest $10 billion in OpenAI

It was only in 2022, Musk testified, that he discovered OpenAI had abandoned its nonprofit mission. At that time, Microsoft was preparing to invest $10 billion in OpenAI—a deal that closed in 2023. 

“I was disturbed to see OpenAI with a $20B valuation,” Musk texted Altman after reading the news. “This is a bait and switch.”

Musk told the jury this was the moment that made him realize “the for-profit is the tail wagging the dog.” He thought Microsoft would give $10 billion only if it expected “a very big financial return.” He argued that this was the point he realized “OpenAI had become, for all intents and purposes, a for-profit company with a $20 billion valuation.” 

“The 2023 deal was different,” Steven Molo, one of Musk’s lawyers, hammered home during his closing argument.

The jury sides with OpenAI

It was up to the jury to decide whether the evidence supported Musk’s claim that he first realized in 2023 that OpenAI was no longer a nonprofit committed to its mission. In the verdict announced today, they found Musk did in fact have reason to think that he was being misled by Altman and Brockman before 2021. They did not address whether he was in fact misled. 

Courts often decide cases on procedural grounds like statutes of limitations when they can, because it can be the cleaner way to resolve a case than to grapple with its merits.

Musk has said he will appeal the decision to the Ninth Circuit Court of Appeals, a federal appellate court that reviews decisions from district courts in California and other states.

Codon Optimization Isn’t Equal: Benchmarking Gene Design for Antibody Expression



Image of Justin Byers

Justin Byers

Founder and CEO
Axio BioPharma

Panelist

Image of Justin Byers

Justin Byers

Justin Byers is the founder and CEO of Axio BioPharma. He holds a BS in biochemistry and molecular biology from Illinois State University and has held leadership roles at Illumina, Danaher, and Fujifilm. Throughout his career, Byers has led commercial, operational, and cross-functional initiatives supporting biologics programs from early development through manufacturing. He has worked closely with scientific teams to scale workflows, improve process rigor, and align technical execution with strategic objectives. At Axio, Byers oversees corporate strategy, partnerships, and scientific direction. His focus is positioning the company at the intersection of structured data and biologics workflow execution. Axio is accelerating biologics development through mAb production services for R&D while partnering with innovators and CDMOs to ensure the data required for rigorous decision making and a digitally enabled future is generated, structured, and accessible.



Image of Daniel Lin-Arlow, PhD

Daniel Lin-Arlow, PhD

Chief Scientific Officer and Co-founder
Ansa Biotechnologies

Panelist

Image of Daniel Lin-Arlow, PhD

Daniel Lin-Arlow, PhD

Daniel Lin-Arlow, PhD, is a scientist-entrepreneur with deep expertise in synthetic biology and biophysics. Motivated by firsthand challenges in obtaining DNA constructs for metabolic engineering in graduate school, he is deeply committed to providing scientists with the DNA constructs they need for their research. As Ansa’s founding CEO, Lin-Arlow grew the company from two employees in 2018 to more than 70 by 2024, raising over $130 million in venture capital and grant funding to support technology development and commercialization. He transitioned to the role of chief scientific officer in 2024, where he leads the development of new applications of the company’s technologies. Lin-Arlow received his PhD from the University of California, Berkeley for his work in Jay Keasling’s lab for developing the DNA synthesis technology commercialized by Ansa. Prior to graduate school, he was a scientific associate at D.E. Shaw Research where he studied the biophysical properties of G protein-coupled receptors, including how drugs bind and modulate their activity. Dan began his scientific career at MIT, where he earned dual SB degrees in math with computer science and biology, and developed computation tools for the analysis of regulation of gene expression at the Broad Institute of MIT and Harvard. Lin-Arlow is a co-inventor of nine patent families and has co-authored scientific publications in Nature, Science, Cell, PNAS, and Nature Biotechnology.



Broadcast Date: 

  • Time: 

Antibody expression titers are key drivers of screening efficiency in discovery, developability, manufacturing economics, and development timelines. Although it is possible to address poor antibody expression by increasing overall batch size and optimizing downstream processes, the root cause often lies in the underlying DNA sequences. Controlled benchmarking studies are helpful for systematically evaluating DNA construct design decisions that impact titers.

In this GEN webinar, Justin Byers and Daniel Lin-Arlow, PhD, examine how enzymatic DNA synthesis and DNA construct design mitigate antibody expression challenges.

Byers will walk through a controlled benchmarking study of codon-optimization approaches, including details of the study design and how structured, gene-to-protein workflows can help identify optimal constructs before they become downstream problems. He will show that under matched CHO and HEK293 conditions, antibody constructs codon-optimized with an AI codon language model had consistently higher transient expression titers than other approaches. The AI codon-optimized sequences contained “complex” features such as repeats and GC skew that challenge traditional gene synthesis processes but were readily manufactured by Ansa’s DNA synthesis platform. These results suggest that complex sequence features can be important for optimal gene expression, which makes the ability to manufacture them as relevant as the codon strategy.

Lin-Arlow will present Ansa’s enzymatic DNA synthesis technology and the benefits to clients working on antibody production, cell and gene therapies, and other synthetic biology applications. Key takeaways include:

  • An AI-powered codon optimization strategy that measurably improves transient antibody expression yield
  • Why controlled side-by-side benchmarking under standardized conditions is the only reliable way to objectively evaluate DNA construct design choices
  • How integrating rigorous sequence evaluation upstream compresses timelines and reduces the risks of expression failures late in development
  • How Ansa’s fully enzymatic DNA synthesis addresses complex sequences, including: High or low GC content, secondary structures, inverted terminal repeats (ITRs), and homopolymers
  • The Ansa On-Time Guarantee—DNA orders shipped on time, or the complete order is free

A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.

Produced with support from:

ANSA Biotechnology logo

The post Codon Optimization Isn’t Equal: Benchmarking Gene Design for Antibody Expression appeared first on GEN – Genetic Engineering and Biotechnology News.

The Download: Musk v. Altman week 3, and Trump’s tech trading

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

Musk v. Altman week 3: Musk and Altman traded blows over each other’s credibility. Now the jury will pick a side.

In the final week of the Musk v. Altman trial, lawyers attacked the credibility of the two tech leaders. Sam Altman was accused of lying and self-dealing, while Elon Musk was portrayed as a power-seeker trying to control artificial general intelligence.

The case unearthed new details about the two arch-rivals and OpenAI’s contested nonprofit status, as well as a golden trophy of a donkey’s ass awarded to an employee who challenged Musk.

Read the full story on the explosive final week of the trial.

—Michelle Kim

Michelle Kim, who’s also a lawyer, has been in court throughout the Musk v. Altman trial. Read her coverage of week 1 and week 2, plus a Q&A on what it was like in the room

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Trump traded hundreds of millions in tech stocks before favorable policy moves
He bought shares in Nvidia, AMD, and Arm ahead of policy boosts. (Quartz)
+ And touted Palantir on Truth Social after buying its stock. (CNBC)
+ His crypto venture and Iran’s top exchange tapped the same networks. (Reuters $)

2 SpaceX plans to list on the Nasdaq stock exchange as soon as June 12
It wants to raise up to $75 billion at a $1.75 trillion valuation. (Reuters $)
+ BlackRock may invest up to $10 billion in the offering. (The Information $)
+ Cerebras’ blockbuster IPO has boosted hopes for the listing. (CNBC)
+ Which is set to dwarf many of the biggest IPOs on ⁠record. (Reuters)

3 Chinese AI groups have pulled ahead of US rivals in video generation
ByteDance and Kuaishou’s models lead in realism and scale. (FT $)
+ AI is fueling China’s short-drama boom. (MIT Technology Review)
+ While its AI labs are betting big on open source. (MIT Technology Review)

4 Iran says it will charge Big Tech for using undersea internet cables
The cables beneath the Strait of Hormuz carry vast digital traffic. (CNN)
+ Tech bosses met at Uber HQ on Saturday to discuss Iran’s future. (404 Media)

5 Samsung has a “last chance” to stop a massive strike over AI
Over 45,000 employees could walk out for 18 days this week. (CNBC
+ They want a bigger share of the AI boom. (FT $)
+ Samsung and its largest labor union will resume talks on Tuesday. (Reuters $)

6 Old oil and gas wells could become a new source of clean energy
US states plan to convert them into geothermal energy assets. (Wired $)
+ A balcony solar boom is coming to the US. (MIT Technology Review)

7 The ChatGPT era has triggered a 30% surge in grades at a top university
Grades inflated in text-heavy courses but remained flat in others. (Axios)
+ Princeton has changed its honor code because of AI cheating. (WSJ $)
+ And real cheating rates may be far higher. (The Times $)

8 Ex-Google CEO Eric Schmidt was fiercely booed during an AI speech
His graduation speech praising AI agents sparked uproar. (The Verge)
+ A populist backlash is building against AI. (MIT Technology Review)

9 Arm faces a US antitrust probe over its chip tech licenses
Regulators are investigating whether it has an illegal monopoly. (Bloomberg $)
+ Qualcomm has accused Arm of anticompetitive conduct. (Reuters $)

10 ArXiv will ban researchers who submit AI slop
Offending authors face year-long bans from the pre-print server. (TechCrunch)

Quote of the day

“When someone offers you a seat on the rocket ship, you do not ask which seat. You just get on.” 

—Ex-Google CEO Eric Schmidt extolls the virtues of AI agents in a graduation speech at the University of Arizona, prompting a chorus of boos.

One More Thing

a gloved hand holding up a microfluidic chip

WYSS INSTITUTE AT HARVARD UNIVERSITY


Is this the end of animal testing?

In a clean room in his lab, Sean Moore peers through a microscope at a bit of human intestinal tissue growing on a plastic chip. It’s one of 24 so-called “organs-on-chips” his team bought three years ago. The technology is designed to mimic human biology—and could reduce the need for animal testing.

The appeal is not only ethical. Around 95% of drugs developed through animal research ultimately fail in people, and early studies suggest organ-on-a-chip systems may offer more accurate insights into how diseases behave and how drugs work. But the field still faces major technical and cost challenges before it can replace animal research.

Find out how organ-on-chip technology could reshape drug testing.

—Harriet Brown

We can still have nice things

A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)

+ Listen to the captivating first recordings of whale songs from 1949.
+ Meet the feline guardians of New York’s corner stores in this photo collection.
+ A newly discovered floor plan allowed historians to pinpoint the location of Shakespeare’s only property in London.
+ A music fan spent decades secretly recording 10,000 local shows. Now the entire collection is available online.

STAT+: Maryland state affordability board places a price cap on Ozempic

The Maryland Prescription Drug Affordability Board agreed to set an upper payment limit for the Ozempic diabetes treatment, marking the second time that the state panel has taken such a step in recent weeks.

The board, which is designed to function like a state utility commission, will now oversee a process to lower the cost of the type 2 diabetes medicine for the state and local governments by January 2027. At the time, the price will be capped at $274 for a 30-day supply, a move the board estimates will save $5.8 million a year.

The expected cost was benchmarked against the maximum fair price paid by Medicare, said Andrew York, executive director of the Maryland board. Meanwhile, the board is expected to begin acting in 2028 to set upper payment limits on high-cost drugs purchased by all Marylanders in the commercial insurance market as well.

Continue to STAT+ to read the full story…

STAT+: White House taps Amazon, GoodRx, and Mark Cuban to bolster TrumpRx

WASHINGTON — The White House announced an expansion of its prescription drug discount platform, TrumpRx, on Monday, adding more than 600 generic drugs to the website.

The expansion comes via a partnership with entrepreneur Mark Cuban’s Cost Plus Drug Company, as well as Amazon Pharmacy and GoodRx, which both also provide drug savings or low-cost prescription medicines.

“By incorporating this massive catalog of low-cost generics at TrumpRx.Gov, consumers will now have one source to ensure that they’re getting the lowest possible cost on their prescriptions,” President Trump said Monday at a White House event. “They have something that they’ve never had before.”

Continue to STAT+ to read the full story…

With no approved vaccine for Ebola outbreak, experts weigh testing a long shot

The latest Ebola outbreak in the Democratic Republic of the Congo, which was only confirmed to be underway at the end of last week, is already the fourth largest on record. The deadly virus is spreading in a conflict zone where recent Ebola experience has shown containment will be a challenge. There is no vaccine that targets the species of the virus that is spreading there, Bundibugyo.

But there is a tiny bit of scientific evidence that suggests the existing licensed Ebola vaccine, Merck’s Ervebo, might offer some protection against this virus, even though it is designed to target a different species of Ebola, Zaire ebolavirus. 

Read the rest…

Multiple Sclerosis Myelin Loss Revealed by Transcriptomic Analysis in Mice

More than one million people across the United States live with multiple sclerosis (MS), a disease that affects the brain, optic nerves, and spine. MS is characterized by overwhelming fatigue, muscle spasms, and vision problems, which can flare up and then subside over days, months, or even years. Studying the underlying damage to the nervous system is key to identifying new treatment paradigms for MS. 

A new study published in Nature Communications titled, “A comparative transcriptomic analysis of mouse demyelination models and multiple sclerosis lesions,” compares two prevailing models, cuprizone (CPZ) and lysophosphatidylcholine (LPC), for the study of myelin loss and regeneration in an MS mouse model. 

Katrina Adams, PhD, Gallagher Assistant Professor at University of Notre Dame, studies the role of the loss and regeneration of myelin on MS progression. As a fatty substance protects nerve cells, myelin envelopes the axons of the brain as they route the electrical signals that carry information throughout the nervous system. The damage and swelling that follow myelin loss in MS form distinct “lesions,” which vary in size, number and location in the nervous system. 

“Our analysis of these two models of myelin loss and regeneration provides a road map based on robust scientific evidence that we hope will advance the study of MS and related diseases,” said Adams. 

While both CPZ and LPC models degrade myelin, the timeline and localization of myelin loss varies. CPZ causes widespread loss of myelin over several weeks while LPC induces a lesion within days. This new research, which was funded by the National Multiple Sclerosis Society, points to specific scenarios in which one model is better suited, depending on which aspect of MS is under investigation. 

“If you’re studying the myelin-producing cells and what’s happening to them in MS—are they stressed, dying or trying to repair?—CPZ is better, since the loss of myelin is more gradual,” Adams said. “For studying the immune cells that respond to the myelin loss, LPC may be better, since the immune response is more aggressive than in CPZ.” 

The team also analyzed the resulting lesions from each preclinical model alongside data obtained from human MS tissue samples. Genetic maps of each type of tissue using single-cell RNA sequencing were constructed to examine the genetic changes that occurred in response to demyelination. 

“By matching each model to features seen in diseased tissue from real patients, we can be sure that we’re targeting things that are actually causing disease in human patients,” Adams said. “There are so many potential paths to follow, so we want to make sure that the path chosen has direct relevance to MS patients.” 

In addition to phenotypic differences, the genetic changes in diseased cells vary between the two models, an area of future exploration for the Adams research group. 

Since MS flare-ups are primarily triggered by the immune system’s reaction to lesions, current clinical treatments focus on quelling this autoimmune response. The regeneration of lost myelin within MS lesions remains a promising yet unrealized drug target. 

“The strategic use of these two preclinical models is essential for translating insights into therapies that might restore lost myelin,” Adams said. “We need to better understand the very process of demyelination in order to treat one of the root causes of this debilitating disorder.” 

The post Multiple Sclerosis Myelin Loss Revealed by Transcriptomic Analysis in Mice appeared first on GEN – Genetic Engineering and Biotechnology News.